Sanofi CFO Jean-Baptiste de Chatillon (L) and CEO Paul Hudson (Romuald Meigneux/Sipa via AP Images)

Sanofi sees downtick in flu sales as it preps for launch of RSV an­ti­body

Sanofi ex­pects its RSV an­ti­body joint­ly de­vel­oped with As­traZeneca will be avail­able next sea­son, ex­ec­u­tive VP of vac­cines Thomas Tri­om­phe an­nounced on the com­pa­ny’s quar­ter­ly call.

Bey­for­tus, al­so known as nir­se­vimab, was ap­proved in the EU back in No­vem­ber and is cur­rent­ly un­der FDA re­view with an ex­pect­ed de­ci­sion com­ing in the third quar­ter of this year. The news comes as the FDA plans to hold ad­vi­so­ry com­mit­tee meet­ings over the next cou­ple months to re­view RSV vac­cines from Pfiz­er and GSK.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.